CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SLC33A1 (ImmuneEditome ID:9197)

1. Gene summary of enriched editing regions for SLC33A1

check button Gene summary
Gene informationGene symbol

SLC33A1

Gene ID

9197

GeneSynonymsACATN|AT-1|AT1|CCHLND|SPG42
GeneCytomap

3q25.31

GeneTypeprotein-coding
GeneDescriptionacetyl-coenzyme A transporter 1|solute carrier family 33 (acetyl-CoA transporter), member 1
GeneModificationdate20230518
UniprotIDO00400;H7C577;A0A2R8YEX5;A0A2R8Y359;A0A2R8Y5I5;A0A2R8YF57;H7C532
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr3:155821445-155826390:-ENST00000392845.6ENSG00000169359.12SLC33A1UTR3AluSp,AluSx1,AluSz,AluSx3,AluSx,FLAM_C,AluJrchr3:155821445-155826390:-.alignment
chr3:155844490-155844767:-ENST00000460729.1ENSG00000169359.12SLC33A1ncRNA_exonicAluSzchr3:155844490-155844767:-.alignment
chr3:155850098-155851421:-ENST00000460729.1ENSG00000169359.12SLC33A1ncRNA_intronicAluSc5,AluJo,AluSx,(TTAT)n,AluSc8chr3:155850098-155851421:-.alignment


Top

2. Tumor-specific enriched editing regions for SLC33A1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr3:155821445-155826390:-KICHEER3.1766e-03image
ENSG00000169359.12,SLC33A1KICHEAG3.1766e-03image
chr3:155821445-155826390:-KIRCEER2.5399e-04image
ENSG00000169359.12,SLC33A1KIRCEAG2.3878e-04image
chr3:155821445-155826390:-LIHCEER1.6224e-02image
ENSG00000169359.12,SLC33A1LIHCEAG2.5747e-02image
chr3:155821445-155826390:-THCAEER7.5759e-03image
ENSG00000169359.12,SLC33A1THCAEAG6.2001e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000169359.12,SLC33A1KIRPCliEAG2.2949e-029.7683e-030.2037image
chr3:155821445-155826390:-KIRPCliEER2.0546e-028.4125e-030.2077image
ENSG00000169359.12,SLC33A1UCSCliEAG1.4231e-038.8097e-03-0.3993image
chr3:155821445-155826390:-UCSCliEER1.4231e-038.8097e-03-0.3993image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for SLC33A1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:155821445-155826390:-GBMEERENSG00000183199,HSP90AB3P0.26543.3293e-021.5717e-070.4176imageNNNAMacrophages_M0GSVA_HALLMARK_G2M_CHECKPOINT
chr3:155821445-155826390:-PRADEERENSG00000177409,SAMD9L0.29578.5729e-092.7333e-260.4586imageNNOP58NADendritic_cells_activatedGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr3:155821445-155826390:-PRADEERENSG00000135899,SP1100.28115.4701e-085.6709e-280.4722imageNNOP58SP110Dendritic_cells_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr3:155821445-155826390:-PRADEERENSG00000173193,PARP140.27986.5506e-085.0163e-200.4020imageNNOP58NAMast_cells_restingGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr3:155821445-155826390:-PRADEERENSG00000137959,IFI44L0.27847.4314e-083.1989e-230.4322imageNNIFI44LDendritic_cells_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr3:155821445-155826390:-PRADEERENSG00000205413,SAMD90.27471.2033e-075.0402e-250.4480imageNNOP58NADendritic_cells_activatedGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr3:155821445-155826390:-PRADEERENSG00000168685,IL7R0.25858.7516e-078.2422e-230.4285imageNNIL7RDendritic_cells_activatedGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr3:155821445-155826390:-PRADEERENSG00000133106,EPSTI10.23648.8305e-061.8065e-220.4254imageNNOP58NADendritic_cells_activatedGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr3:155821445-155826390:-PRADEERENSG00000231721,LINC-PINT0.20671.4480e-042.0186e-260.4597imageNNOP58NADendritic_cells_activatedGSVA_HALLMARK_PEROXISOME
chr3:155821445-155826390:-PRADEERENSG00000242588,RP11-274B21.140.19244.2070e-047.8000e-210.4099imageNNOP58NAT_cells_CD4_memory_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results



Top

4. Enriched editing regions and immune related splicing for SLC33A1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000169359.12,SLC33A1
ESCAEAGMEXENSG00000099385.7chr1630851245:30852322:30888859:30888889:30892585:30892714:30893211:30893290-0.37283.8243e-031.6317e-07-0.4597imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184BCL7CDendritic_cells_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr3:155821445-155826390:-
ESCAEERMEXENSG00000129657.10chr1777215831:77215958:77216049:77216127:77216137:77216387:77216413:772168020.16891.4884e-023.3937e-080.5273imageNNOP58NA
chr3:155821445-155826390:-
ESCAEERMEXENSG00000129657.10chr1777215831:77215958:77216049:77216127:77216140:77216387:77216413:772168020.16891.4884e-023.3937e-080.5273imageNNOP58NA
chr3:155821445-155826390:-
ESCAEERMEXENSG00000129657.10chr1777215831:77215958:77216049:77216127:77216205:77216387:77216413:772168020.16891.4884e-023.3937e-080.5273imageNNOP58NA
chr3:155821445-155826390:-
ESCAEERMEXENSG00000129657.10chr1777215831:77215958:77216049:77216127:77216215:77216387:77216413:772168020.16891.4884e-023.3709e-080.5274imageNNOP58NA
chr3:155821445-155826390:-
ESCAEERMEXENSG00000129657.10chr1777215831:77215958:77216049:77216127:77216202:77216387:77216413:772168020.15804.7395e-026.2376e-080.5162imageNNOP58NA
chr3:155821445-155826390:-
PCPGEERMEXENSG00000064115.6chr1226982772:26982859:26990449:26990627:27003235:27003390:27014077:27014211-0.37243.5837e-048.5401e-08-0.4057imageNNOP58NANK_cells_restingGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000169359.12,SLC33A1
PCPGEAGMEXENSG00000204852.11chr12110641541:110641627:110642248:110642389:110644972:110647336:110647748:1106477570.44468.1790e-061.0843e-080.4188imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28B;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RNF219;SF3A3;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;U2AF1;U2AF2;UPF1;YTHDC1;ZNF184NANeutrophilsGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000169359.12,SLC33A1
PCPGEAGMEXENSG00000164828.13chr7843340:843520:848417:849603:849922:851482:851949:8520430.43815.0571e-062.0891e-080.4204imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAB_cells_naiveGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000169359.12,SLC33A1
PCPGEAGMEXENSG00000169045.13chr5179616157:179616218:179616868:179616958:179620891:179621397:179623036:179623164-0.41546.4429e-051.5954e-09-0.4397imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

5. Enriched editing regions and immune infiltration for SLC33A1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr3:155821445-155826390:-ACCEERDendritic_cells_resting4.5870e-020.2412image
ENSG00000169359.12,SLC33A1ACCEAGDendritic_cells_resting4.5870e-020.2412image
chr3:155821445-155826390:-BLCAEERMacrophages_M23.4471e-020.1508image
ENSG00000169359.12,SLC33A1BLCAEAGMacrophages_M22.5449e-020.1584image
chr3:155821445-155826390:-BRCAEERT_cells_CD87.8422e-03-0.0887image
ENSG00000169359.12,SLC33A1BRCAEAGT_cells_CD81.3305e-02-0.0824image
chr3:155821445-155826390:-CESCEERMacrophages_M02.3089e-020.1564image
ENSG00000169359.12,SLC33A1CESCEAGMacrophages_M03.3690e-020.1459image
chr3:155821445-155826390:-CHOLEERNK_cells_activated1.2758e-020.4289image
ENSG00000169359.12,SLC33A1CHOLEAGNK_cells_activated1.2758e-020.4289image
ENSG00000169359.12,SLC33A1COADEAGDendritic_cells_activated1.9407e-020.1981image
ENSG00000169359.12,SLC33A1ESCAEAGDendritic_cells_resting2.6183e-02-0.1866image
chr3:155821445-155826390:-GBMEERMast_cells_resting2.3278e-020.1877image
ENSG00000169359.12,SLC33A1GBMEAGMast_cells_resting2.3278e-020.1877image
chr3:155821445-155826390:-KIRPEERMacrophages_M11.8238e-030.2028image
ENSG00000169359.12,SLC33A1KIRPEAGMacrophages_M12.0850e-030.2002image
chr3:155821445-155826390:-LGGEERDendritic_cells_activated4.8289e-040.1584image
ENSG00000169359.12,SLC33A1LGGEAGDendritic_cells_activated4.8289e-040.1584image
chr3:155821445-155826390:-LUADEERDendritic_cells_activated1.7515e-020.1230image
ENSG00000169359.12,SLC33A1LUADEAGDendritic_cells_activated2.3882e-020.1168image
chr3:155821445-155826390:-MESOEERT_cells_follicular_helper1.1841e-020.3230image
ENSG00000169359.12,SLC33A1MESOEAGT_cells_follicular_helper1.1841e-020.3230image
chr3:155821445-155826390:-OVEERNeutrophils4.5340e-040.2242image
ENSG00000169359.12,SLC33A1OVEAGB_cells_naive4.7801e-03-0.1808image
chr3:155821445-155826390:-PAADEERNK_cells_activated9.8258e-04-0.3114image
ENSG00000169359.12,SLC33A1PAADEAGNK_cells_activated9.8258e-04-0.3114image
chr3:155821445-155826390:-PCPGEERNeutrophils1.1872e-020.1914image
ENSG00000169359.12,SLC33A1PCPGEAGNeutrophils1.1872e-020.1914image
chr3:155821445-155826390:-PRADEERDendritic_cells_activated4.1881e-060.2085image
ENSG00000169359.12,SLC33A1PRADEAGMast_cells_resting2.4500e-03-0.1381image
chr3:155821445-155826390:-SARCEERMacrophages_M12.6945e-060.3712image
ENSG00000169359.12,SLC33A1SARCEAGMacrophages_M12.6945e-060.3712image
chr3:155821445-155826390:-STADEERT_cells_CD4_memory_activated1.9347e-030.1900image
chr3:155844490-155844767:-STADEERT_cells_CD4_memory_activated3.8698e-02-0.2591image
chr3:155850098-155851421:-STADEERMacrophages_M04.2750e-030.5415image
ENSG00000169359.12,SLC33A1STADEAGT_cells_CD4_memory_activated2.0984e-020.1377image
chr3:155821445-155826390:-TGCTEERDendritic_cells_activated6.3274e-030.3515image
ENSG00000169359.12,SLC33A1TGCTEAGDendritic_cells_activated7.4653e-030.3421image
chr3:155821445-155826390:-THCAEERB_cells_naive1.0042e-040.1772image
ENSG00000169359.12,SLC33A1THCAEAGB_cells_naive2.8719e-040.1652image
chr3:155821445-155826390:-THYMEERT_cells_gamma_delta2.9074e-020.2383image
ENSG00000169359.12,SLC33A1THYMEAGT_cells_gamma_delta1.7115e-020.2565image
chr3:155821445-155826390:-UCECEERT_cells_gamma_delta8.2873e-040.3101image
ENSG00000169359.12,SLC33A1UCECEAGPlasma_cells1.0421e-030.2994image
chr3:155821445-155826390:-UCSEERB_cells_naive2.8286e-02-0.3386image
ENSG00000169359.12,SLC33A1UCSEAGB_cells_naive2.8286e-02-0.3386image


Top

6. Enriched editing regions and immune gene sets for SLC33A1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000169359.12,SLC33A1LUADEAG9.3943e-030.13421.8820e-030.16024.5184e-030.14653.6783e-020.1080image
chr3:155821445-155826390:-LUADEER4.7110e-030.14602.5309e-030.15591.4744e-030.16411.4996e-020.1259image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000169359.12,SLC33A1ACCGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.6807e-020.2402image
chr3:155821445-155826390:-ACCGSVA_HALLMARK_MITOTIC_SPINDLEEER4.6807e-020.2402image
ENSG00000169359.12,SLC33A1BLCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG5.6233e-030.1956image
chr3:155821445-155826390:-BLCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.0358e-030.2320image
ENSG00000169359.12,SLC33A1BRCAGSVA_HALLMARK_UV_RESPONSE_DNEAG2.5025e-030.1006image
chr3:155821445-155826390:-BRCAGSVA_HALLMARK_UV_RESPONSE_DNEER8.2041e-040.1115image
chr3:155821445-155826390:-CESCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.8540e-020.1620image
ENSG00000169359.12,SLC33A1CESCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.8587e-020.1422image
chr3:155821445-155826390:-CHOLGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER6.2647e-030.4660image
ENSG00000169359.12,SLC33A1CHOLGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG6.2647e-030.4660image
ENSG00000169359.12,SLC33A1ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.0479e-040.2882image
chr3:155821445-155826390:-ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.1236e-040.2891image
chr3:155821445-155826390:-GBMGSVA_HALLMARK_HEME_METABOLISMEER3.0724e-020.1789image
ENSG00000169359.12,SLC33A1GBMGSVA_HALLMARK_HEME_METABOLISMEAG3.0724e-020.1789image
chr3:155821445-155826390:-HNSCGSVA_HALLMARK_KRAS_SIGNALING_UPEER2.6189e-040.2548image
ENSG00000169359.12,SLC33A1HNSCGSVA_HALLMARK_KRAS_SIGNALING_UPEAG2.8802e-040.2525image
chr3:155821445-155826390:-KICHGSVA_HALLMARK_PROTEIN_SECRETIONEER1.3939e-030.4241image
ENSG00000169359.12,SLC33A1KICHGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.3939e-030.4241image
ENSG00000169359.12,SLC33A1KIRCGSVA_HALLMARK_APICAL_JUNCTIONEAG2.1034e-040.1947image
chr3:155821445-155826390:-KIRCGSVA_HALLMARK_KRAS_SIGNALING_DNEER8.3932e-050.2066image
ENSG00000169359.12,SLC33A1KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.1614e-040.2493image
chr3:155821445-155826390:-KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEER8.4460e-050.2541image
chr3:155821445-155826390:-LGGGSVA_HALLMARK_PROTEIN_SECRETIONEER2.4150e-060.2129image
ENSG00000169359.12,SLC33A1LGGGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.4150e-060.2129image
chr3:155821445-155826390:-LIHCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.2921e-070.2742image
ENSG00000169359.12,SLC33A1LIHCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.6471e-050.2264image
chr3:155821445-155826390:-LUADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER3.7769e-030.1496image
ENSG00000169359.12,SLC33A1LUADGSVA_HALLMARK_G2M_CHECKPOINTEAG6.0994e-030.1416image
chr3:155821445-155826390:-LUSCGSVA_HALLMARK_MITOTIC_SPINDLEEER3.1995e-030.1493image
ENSG00000169359.12,SLC33A1LUSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.6426e-030.1473image
ENSG00000169359.12,SLC33A1MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG9.7838e-030.3310image
chr3:155821445-155826390:-MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER9.7838e-030.3310image
ENSG00000169359.12,SLC33A1OVGSVA_HALLMARK_MYC_TARGETS_V1EAG9.4391e-050.2483image
chr3:155821445-155826390:-OVGSVA_HALLMARK_MYC_TARGETS_V1EER1.1924e-050.2779image
chr3:155821445-155826390:-PAADGSVA_HALLMARK_NOTCH_SIGNALINGEER1.0111e-020.2454image
ENSG00000169359.12,SLC33A1PAADGSVA_HALLMARK_NOTCH_SIGNALINGEAG1.0111e-020.2454image
chr3:155821445-155826390:-PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEER1.2901e-050.3258image
ENSG00000169359.12,SLC33A1PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.2901e-050.3258image
chr3:155821445-155826390:-PRADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.5516e-060.2175image
ENSG00000169359.12,SLC33A1PRADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.6244e-060.2128image
ENSG00000169359.12,SLC33A1READGSVA_HALLMARK_PEROXISOMEEAG1.5286e-02-0.3316image
chr3:155821445-155826390:-READGSVA_HALLMARK_COMPLEMENTEER3.4668e-030.3981image
ENSG00000169359.12,SLC33A1SARCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.1964e-030.2612image
chr3:155821445-155826390:-SARCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.1964e-030.2612image
chr3:155821445-155826390:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.5418e-020.1227image
ENSG00000169359.12,SLC33A1SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.4287e-020.1231image
chr3:155850098-155851421:-STADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.8288e-02-0.4085image
ENSG00000169359.12,SLC33A1STADGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.9729e-03-0.1556image
chr3:155821445-155826390:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.5911e-030.1786image
chr3:155844490-155844767:-STADGSVA_HALLMARK_APICAL_SURFACEEER2.2058e-020.2858image
chr3:155821445-155826390:-TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEER2.5098e-020.2915image
ENSG00000169359.12,SLC33A1THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG1.5222e-150.3538image
chr3:155821445-155826390:-THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER6.7184e-180.3807image
chr3:155821445-155826390:-THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER4.1681e-020.2228image
ENSG00000169359.12,SLC33A1THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.8511e-020.2363image
ENSG00000169359.12,SLC33A1UCSGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG3.8438e-020.3206image
chr3:155821445-155826390:-UCSGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.8438e-020.3206image


Top

7. Enriched editing regions and drugs for SLC33A1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000169359.12,SLC33A1ACCJNK.9LEAG4.1369e-03-0.3410image
chr3:155821445-155826390:-ACCJNK.9LEER4.1369e-03-0.3410image
ENSG00000169359.12,SLC33A1BLCAAUY922EAG4.5463e-04-0.2463image
chr3:155821445-155826390:-BLCAAUY922EER1.2402e-03-0.2285image
ENSG00000169359.12,SLC33A1BRCAAZD.0530EAG5.0576e-03-0.0934image
chr3:155821445-155826390:-BRCAAZD.0530EER8.7181e-03-0.0876image
chr3:155821445-155826390:-CESCBMS.708163EER1.5394e-03-0.2167image
ENSG00000169359.12,SLC33A1CESCGW.441756EAG2.4859e-020.1541image
chr3:155821445-155826390:-CHOLAZD8055EER1.6218e-020.4154image
ENSG00000169359.12,SLC33A1CHOLAZD8055EAG1.6218e-020.4154image
ENSG00000169359.12,SLC33A1COADMG.132EAG2.7496e-020.1870image
chr3:155821445-155826390:-ESCABleomycinEER4.7245e-04-0.3012image
ENSG00000169359.12,SLC33A1ESCABleomycinEAG2.5332e-03-0.2515image
ENSG00000169359.12,SLC33A1GBMBMS.754807EAG2.0981e-030.2526image
chr3:155821445-155826390:-GBMBMS.754807EER2.0981e-030.2526image
ENSG00000169359.12,SLC33A1HNSCCI.1040EAG6.1888e-04-0.2388image
chr3:155821445-155826390:-HNSCCI.1040EER6.2531e-04-0.2392image
chr3:155821445-155826390:-KICHCI.1040EER4.2995e-03-0.3826image
ENSG00000169359.12,SLC33A1KICHCI.1040EAG4.2995e-03-0.3826image
chr3:155821445-155826390:-KIRCEmbelinEER6.1912e-03-0.1446image
ENSG00000169359.12,SLC33A1KIRCEmbelinEAG2.9621e-03-0.1566image
ENSG00000169359.12,SLC33A1KIRPAxitinibEAG1.1138e-06-0.3121image
chr3:155821445-155826390:-KIRPAxitinibEER1.0474e-06-0.3128image
ENSG00000169359.12,SLC33A1LGGGW843682XEAG1.4508e-040.1722image
chr3:155821445-155826390:-LGGGW843682XEER1.4508e-040.1722image
chr3:155821445-155826390:-LIHCBleomycinEER8.5394e-040.1830image
ENSG00000169359.12,SLC33A1LIHCAZ628EAG6.6774e-030.1488image
ENSG00000169359.12,SLC33A1LUADGemcitabineEAG1.7796e-03-0.1611image
chr3:155821445-155826390:-LUADGemcitabineEER1.5646e-03-0.1632image
chr3:155821445-155826390:-LUSCCGP.082996EER2.5805e-02-0.1132image
ENSG00000169359.12,SLC33A1LUSCCGP.082996EAG2.6580e-02-0.1126image
chr3:155821445-155826390:-MESOMetforminEER1.3629e-020.3169image
ENSG00000169359.12,SLC33A1MESOMetforminEAG1.3629e-020.3169image
chr3:155821445-155826390:-OVCCT007093EER1.3323e-040.2436image
ENSG00000169359.12,SLC33A1OVCCT007093EAG7.7507e-050.2513image
ENSG00000169359.12,SLC33A1PAADCI.1040EAG2.0856e-03-0.2917image
chr3:155821445-155826390:-PAADCI.1040EER2.0856e-03-0.2917image
ENSG00000169359.12,SLC33A1PCPGBX.795EAG1.9395e-040.2805image
chr3:155821445-155826390:-PCPGBX.795EER1.9395e-040.2805image
chr3:155821445-155826390:-PRADJNK.Inhibitor.VIIIEER4.6384e-11-0.2948image
ENSG00000169359.12,SLC33A1PRADJNK.Inhibitor.VIIIEAG7.7800e-09-0.2599image
ENSG00000169359.12,SLC33A1READCisplatinEAG3.9900e-06-0.5862image
chr3:155821445-155826390:-READCisplatinEER7.1157e-05-0.5224image
chr3:155821445-155826390:-SARCGW.441756EER1.0095e-030.2650image
ENSG00000169359.12,SLC33A1SARCGW.441756EAG1.0095e-030.2650image
chr3:155821445-155826390:-SKCMMethotrexateEER2.4967e-02-0.1323image
ENSG00000169359.12,SLC33A1SKCMDasatinibEAG2.4888e-02-0.1313image
chr3:155850098-155851421:-STADJNJ.26854165EER1.0760e-040.6865image
ENSG00000169359.12,SLC33A1STADAUY922EAG1.6061e-02-0.1435image
chr3:155844490-155844767:-STADCisplatinEER2.2888e-020.2841image
chr3:155821445-155826390:-STADCI.1040EER2.2203e-03-0.1875image
chr3:155821445-155826390:-TGCTBAY.61.3606EER5.8903e-04-0.4343image
ENSG00000169359.12,SLC33A1TGCTElesclomolEAG7.5116e-03-0.3418image
ENSG00000169359.12,SLC33A1THCAAMG.706EAG1.6928e-130.3286image
chr3:155821445-155826390:-THCAAMG.706EER6.7801e-150.3464image
ENSG00000169359.12,SLC33A1THYMCytarabineEAG1.9033e-020.2524image
chr3:155821445-155826390:-THYMCytarabineEER1.8669e-020.2562image
ENSG00000169359.12,SLC33A1UCECMethotrexateEAG2.7593e-02-0.2037image
chr3:155821445-155826390:-UCSMetforminEER1.2376e-03-0.4817image
ENSG00000169359.12,SLC33A1UCSMetforminEAG1.2376e-03-0.4817image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType